A review of the venous thrombotic issues associated with multiple myeloma

References

• Falanga A, Russo L. Epidemiology, risk and outcomes of venous thromboembolism in cancer. Hamostaseologie. 2012;32:115–125.
   PubMed Web of Science ®Google Scholar
• Cronin-Fenton DP, Søndergaard FF, Pedersen LA, et al. Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006. Br J Cancer. 2010 Sep 28;103(7):947–953.
   PubMed Web of Science ®Google Scholar
• Louzada ML, Majeed H, Dao V, et al. Risk of recurrent venous thromboembolism according to malignancy characteristics in patients with cancer-associated thrombosis: a systematic review of observational and intervention studies. Blood Coagul Fibrinol. 2011;22:86–91.
   PubMed Web of Science ®Google Scholar
• International Association for Research on Cancer (IARC). Estimated incidence and mortality of multiple myeloma and immunoproliferative diseases in Europe in 2012 (both sexes). [ cited 2015 Dec 12]. Available from: http://eco.iarc.fr/eucan/Cancer.aspx?Cancer=39
   Google Scholar
• Surveillance Epidemiology and End Results SEER 2006-2010. [ cited 2015 Nov 15]. Available from: http://www.seer.cancer.gob/statfacts/html/mulmy.html.
   Google Scholar
• De Stefano V, Za T, Rossi E. Venous thromboembolism in multiple myeloma. Semin Thromb Hemost. 2014;40:338–347.
   PubMed Web of Science ®Google Scholar
• Isozumi Y, Arai R, Fujimoto K, et al. Activation of coagulation by lenalidomide-based regimens for the treatment of multiple myeloma. PLoS ONE. 2013;8(5):e64369.
   Google Scholar
• Kristinsson SY. Thrombosis in multiple myeloma. Hematol AM Soc Hematol Educ Program. 2010;2010:437–444.
   PubMedGoogle Scholar
• Leleu X, Rodon P, Hulin C, et al. MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs. Thromb Haemost. 2013;110:844–851.
   PubMed Web of Science ®Google Scholar
• Zangari M, Tricot G, Polavaram L, et al. Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. J Clin Oncol. 2010;28(1):132–135.
   PubMed Web of Science ®Google Scholar
• Kristinsson SY, Pfeiffer RM, Björkholm M, et al. Thrombosis is associated with inferior survival in multiple myeloma. Haematologica. 2012;97(10):1603–1607.
   PubMed Web of Science ®Google Scholar
• Gregersen H, Nørgaard M, Severinsen MT, et al. Monoclonal gammopathy of undetermined significance and risk of venous thromboembolism. Eur J Haematol. 2011;86(2):129–134.
   PubMed Web of Science ®Google Scholar
• Kristinsson SY, Pfeiffer RM, Bjorkhom M, et al. Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood. 2008;112(9):3582–3586.
   PubMed Web of Science ®Google Scholar
• Za T, De Stefano V, Rossi E, et al. Multiple Myeloma GIMEMA-Latinum Region Working Group. Arterial and venous thrombosis in patients with monoclonal gammopathy of undetermined significance: incidence and risk factors in a cohort of 1491 patients. Br J of Haematol. 2013;160(5):673–679.
   PubMed Web of Science ®Google Scholar
• Crowley MP, Eustace JA, O’Shea SI, et al. Venous thromboembolism in patients with myeloma: incidence and risk factors in a “real-world” population. Clin Appl Thromb Hemmost. 2014 Sep;20(6):600–606.
   PubMed Web of Science ®Google Scholar
• Leebeek FW, Kruip MJ, Sonneveld P. Risk and management of thrombosis in multiple myeloma. Thromb Res. 2012 Apr;129(Suppl 1):S88–92.
   PubMed Web of Science ®Google Scholar
• Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy associated thrombosis. Blood. 2008;111:4902–4907.
   PubMed Web of Science ®Google Scholar
• Dutia M, White RH, Wun T. Risk assessment models for cancer-associated venous thromboembolism. Cancer. 2012;118:3468–3476.
   PubMed Web of Science ®Google Scholar
• Cini M, Zamagni E, Valdré L, et al. Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin. Eur J Haematol. 2010;84:484–492.
   PubMed Web of Science ®Google Scholar
• Zamagni E, Brioli A, Tacchetti P, et al. Multiple Myeloma, Venous Thromboembolism and treatment related risk of thrombosis. Semin Thromb Hemost. 2011;37(3):209–219.
   PubMed Web of Science ®Google Scholar
• Kwaan HC. Hyperviscosity in plasma cell dyscrasias. Clin Hemorheol Microcirc. 2013;55(1):75–83.
   PubMed Web of Science ®Google Scholar
• Huang H1, Li H, Li D. Effect of serum monoclonal protein concentration on haemostasis in patients with multiple myeloma. Blood Coagul Fibrinol. 2015 Jul;26(5):555–559.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Palladino C. Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance. Ther Adv Drug Saf. 2012;3(5):255–266.
   PubMedGoogle Scholar
• Baz R, Li L, Kottke-Marchant K, et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc. 2005;80:1568–1574.
   PubMed Web of Science ®Google Scholar
• Robak M1, Treliński J, Chojnowski K. Hemostatic changes after 1 month of thalidomide and dexamethasone therapy in patients with multiple myeloma. Med Oncol. 2012 Dec;29(5):3574–3580.
   PubMed Web of Science ®Google Scholar
• Elabedin HM, Hassan EA, El Amir MA, et al. The clinical utility of tissue factor level as biomarker in multiple myeloma. J Americal Sci. 2012;8(12):255–261.
   Google Scholar
• Geddings JE, Mackman N. Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients. Blood. 2013;122(11):1873–1880.
   PubMed Web of Science ®Google Scholar
• Owens AP, Mackman N 3rd. Microparticles in hemostasis and thrombosis. Circ Res. 2011;108:1284–1297.
   PubMed Web of Science ®Google Scholar
• Nomura S, Niki M, Nisizawa T, et al. Microparticles as biomarkers of blood coagulation in cancer. Biomark Cancer. 2015;7:51–56.
   PubMedGoogle Scholar
• Auwerda JJ1, Yuana Y, Osanto S, et al. Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma. Thromb Haemost. 2011 Jan;105(1):14–20.
   PubMed Web of Science ®Google Scholar
• Cesarman-Maus G, Braggio E, Maldonado H, et al. Absence of tissue factor expression by neoplastic plasma cells in multiple myeloma. Leukemia. 2012;26:1671–1674.
   PubMed Web of Science ®Google Scholar
• Undas A1, Zubkiewicz-Usnarska L, Helbig G, et al. Induction therapy alters plasma fibrin clot properties in multiple myeloma patients: association with thromboembolic complications. Blood Coagul Fibrinol. 2015;26(6):621–627.
   PubMed Web of Science ®Google Scholar
• Bagratuni T, Kastritis E, Politou M, et al. Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens. Am J Hematol. 2013;88:765–770.
   PubMed Web of Science ®Google Scholar
• Zangari M, Berno T, Zhan F, et al. Activated protein C resistance as measured by residual factor V after Russell’s viper venom and activated protein C treatment analyzed as a continuous variable in multiple myeloma and normal controls. Blood Coagul Fibrinol. 2011;22(5):420–423.
   PubMed Web of Science ®Google Scholar
• Cesarman-Maus G, Braggio E, Fonseca R. Thrombosis in multiple myeloma (MM). Hematology. 2012;17(Suppl 1):S177–80.
   PubMed Web of Science ®Google Scholar
• Carrier M, Le Gal G, Tay J, et al. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost. 2011;9:653–663.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Swern AS, Li JS, et al. Efficacy and safety of long term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood Cancer J. 2014;4:e257.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11:29–37m.
   PubMed Web of Science ®Google Scholar
• Rosovsky R, Hong F, Tocco D, et al. Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study. Br J Haematol. 2013;160(3):351–358.
   PubMed Web of Science ®Google Scholar
• Zonder JA, Crowley J, Hussein MA, et al. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood. 2010;116(26):5838–5841.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Hajek R, Delforge M, et al. MM-015 Investigators. Continuous lenalidomide treatment in patients with recurrent multiple myeloma. Cancer. 2013;119(20):3680–3686.
   PubMed Web of Science ®Google Scholar
• Larocca A, Cavallo F, Evangelista A, et al. Thromboprophylaxis for newly diagnosed multiple myeloma patients treated with lenalidomide-based regimens: a randomized phase iii study of aspirin vs enoxaparin. Haematologica. 2011;96:210.
   Google Scholar
• Hanaizi Z, Flores B, Hemmings R, et al. The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use. Oncologist. 2015;20(3):329–334.
   PubMed Web of Science ®Google Scholar
• Richardson P, Siegel D, Vij R, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014;123(12):1826–1832.
   PubMed Web of Science ®Google Scholar
• Fouquet G, Tardy S, Demarquette H, et al. Efficacy and safety profile of long term exposure to lenalidomide in patients with recurrent multiple myeloma. Cancer. 2013;119(20):3680–3686.
   PubMed Web of Science ®Google Scholar
• Iida S, Chou T, Okamoto S, et al. Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma. Int J Hematol. 2010 Jul;92(1):118–126.
   PubMed Web of Science ®Google Scholar
• Attal M, Lauwers-Cances V, Marit G, et al. IFM Investigators. Lenalidomide maintenance after stem cell transplantation for multiple myeloma. N Engl J Med 2012;366(19):1782–1791.
   PubMed Web of Science ®Google Scholar
• Scott LJ. Pomalidomide: a review of its use in patients with recurrent multiple myeloma. Drugs. 2014 Apr;74(5):549–562.
   PubMed Web of Science ®Google Scholar
• Miguel JS, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomized, open-label, phase 3 trial. Lance Oncol. 2013;14(11):1055–1066.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Leleu X, Palumbo A, et al. Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Leukemia. 2014;28:1573–1585.
   PubMed Web of Science ®Google Scholar
• Leleu X, Attal M, Moreau P, et al. Phase II study of 2 modalities of pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. IFM 2009-02. ASH Annu Meet Abstr. 2010;116(21):859.
   Google Scholar
• Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia. 2010;24:1934–1939.
   PubMed Web of Science ®Google Scholar
• Zangari M1, Fink L, Zhan F, et al. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens. Clin Lymphoma Myeloma Leuk. 2011 Apr;11(2):228–236.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Siegel D, Baz R, et al. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood. 2013;121(11):1961–1967.
   PubMed Web of Science ®Google Scholar
• Leleu X, Attal M, Arnulf B, et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02. Blood. 2013;121(11):1968–1975.
   PubMed Web of Science ®Google Scholar
• Lacy MQ, Allred JB, Gertz MA, et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of two dosing strategies in dual-refractory disease. Blood. 2011;118:2970–2975.
   PubMed Web of Science ®Google Scholar
• Rupa-Matysek J, Gil L, Wojtasińska E, et al. Inhibitory effects of bortezomib on platelet aggregation in patients with multiple myeloma. Thromb Res. 2014;134(2):404–411.
   PubMed Web of Science ®Google Scholar
• Abdullah WZ, Roshan TM, Hussin A, et al. Increased PAC-1 expression among patients with multiple myeloma on concurrent thalidomide and warfarin. Blood Coagul Fibrinol. 2013;24(8):893–895.
   PubMed Web of Science ®Google Scholar
• Gandhi AK, Kang J, Capone L, et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Current Cancer Drug Targets. 2010;10:155–167.
   PubMed Web of Science ®Google Scholar
• Engelhardt M, Terpos E, Kleber M, et al. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica. 2014;99(2):232–242.
   PubMed Web of Science ®Google Scholar
• Lee SE, Jeon YW, Yoon JH, et al. Clinical outcomes of venous thromboembolism with dalteparin therapy in multiple myeloma patients. Thromb Res. 2015 Nov;136(5):974–979.
   PubMed Web of Science ®Google Scholar
• Anaissie EJ, Coleman EA, Goodwin JA, et al. Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis. Cancer. 2011;118:549–557.
   PubMed Web of Science ®Google Scholar
• Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373:621–631.
   PubMed Web of Science ®Google Scholar
• Liu YC, Szmania S, Van Rhee F. Profile of elotozumab and its potential in treatment of multiple myeloma. Blood Lympaht Cancer. 2014;2014(4):15–27.
   PubMedGoogle Scholar
• Laubach JP, Tai YT, Richardson PG, et al. Daratumumab granted breakthrough drug status. Expert Opin Investig Drugs. 2014;23(4):445–452.
   PubMed Web of Science ®Google Scholar
• Plesner T, Arkenau H-T, Lokhorst HM, et al. Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma [abstract]. Blood. 2014;124:21.
   Web of Science ®Google Scholar
• Palumbo A, Cavo M, Bringhen S. Aspirin, warfarin or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol. 2011;29(8):986–993.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Palumbo A, Attal M, et al. Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: a consensus statement. Leukemia. 2011;25(5):749–760.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Rajkumar SV, San Miguel JF, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2014;32(6):587–600.
   PubMed Web of Science ®Google Scholar
• Terpos E, Kleber M, Engelhardt M, et al. European Myeloma Network guidelines for the management of multiple myeloma-related complications. Haematologica. 2015;100(10):1254–1266.
   PubMed Web of Science ®Google Scholar
• Streiff MB, Bockenstedt PL, Cataland SR, et al. Venous thromboembolic disease. Clin Pract Guidel Oncol.J Natl Compr Canc Netw. 2011;9:714–777.
   PubMed Web of Science ®Google Scholar
• Louzada M, Mateos MV, Siqueira L, et al. Comparing the efficacy of aspirin or low molecular weight Heparin or vitamin K antagonists in the risk of thromboembolic events in patients with multiple myeloma treated with lenalidomide-based therapy. Blood. 2015;126:23.
   Google Scholar
• McCarthy P, Owzar K, Hofmeister C, et al. Lenalidomide after Stem-cell transplantation for multiple myeloma. N Eng J Med. 2012;366:1770–1781.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed Multiple Myeloma. N Eng J Med. 2012;366:1759–1769.
   PubMed Web of Science ®Google Scholar
• Lyman G, Khorana A, Kuderer N, et al. Venous thromboembolism prophylaxis and treatment in aptients with cancer: American society of clinical oncology clinical practice guideline update. Clin Oncol. 2013;31:2189–2204.
   Web of Science ®Google Scholar
• Palumbo A, Larocca A, Genuardi M. Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial. Haematologica. 2010;95(7):1144–1149.
   PubMed Web of Science ®Google Scholar
• Ay C, Dunkler D, Marosi C, et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116:5377–5382.
   PubMed Web of Science ®Google Scholar
• Ay C, Dunkler D, Simanek R, et al. Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol. 2011;29:2099–2103.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Khorana AA, Kudere NM, et al. Venous thromboemboembolism prophylaxis nad treatment in patients with cancer. Americal Soceity of Clinical Oncology clinical practice guidelin update. J. Clin Oncol. 2013;31:2189–2204.
   PubMed Web of Science ®Google Scholar
• Connolly GC, Khorana AA. Emerging risk stratification approaches to cancer-associated thrombosis: risk factors, biomarkers and a risk score. Thromb Res. 2010;125(Suppl 2):S1–S7.
   Google Scholar
• Crowley MP, Kevane B, Eustace JA, et al. Thromboprophylaxis in myeloma: what is happening outside of clinical trials? Ir Med J. 2014 Oct;107(9):281–284.
   Google Scholar
• Ferroni P, Martini F, Portarena I, et al. Novel high-sensitive D-dimer determination predicts chemotherapy-associated venous thromboembolism in intermediate risk lung cancer patients. Clin Lung Cancer. 2012;13:482–487. wol
   PubMed Web of Science ®Google Scholar
• Dargaud Y, Wolberg AS, Luddington R, et al. Evaluation of a standardized protocol for thrombin generation measurement using the calibrated automated thrombogram: an international multicentre study. Thromb Res. 2012;130(6):929–934.
   PubMed Web of Science ®Google Scholar
• Gardiner C, Harrison P, Belting P, et al. Extracellular vesicles, tissue factor and thrombosis – discussion themes of the ISEV 2014 Educational Day. J Extracell Vesicles 2015;[cited Dec 2015 27]. Available from: <http://www.journalofextracellularvesicles.net/index.php/jev/article/view/26901.
   PubMed Web of Science ®Google Scholar
• Manly D, Wang J, Glover SL, et al. Increased microparticle tissue factor activity in cancer patients with venous thromboembolism. Thromb Res. 2010;125:511–512.
   PubMed Web of Science ®Google Scholar
• Nomura S, Niki M, Nisizawa T, et al. Microparticles as biomarkers in blood coagulation in cancer. Biom in Cancer. 2015;7:51–56.
   PubMedGoogle Scholar
• Chaari M, Ayadi I, Rousseau A, et al. Impact of breast cancer stage, time from diagnosis and chemotherapy on plasma and cellular biomarkers of hypercoagulability. BMC Cancer. 2014;14:991.
   PubMed Web of Science ®Google Scholar